Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

3(50.0%)

6Total

Phase 2(3)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02796352Phase 2Terminated

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

Role: lead

NCT00374140Phase 2Completed

Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer

Role: lead

NCT00471471Phase 1Completed

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Role: lead

NCT00610857Phase 2Completed

Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma

Role: lead

NCT01233687Phase 1Completed

AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer

Role: lead

NCT00958022Phase 1Terminated

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

Role: lead

All 6 trials loaded